OBJECTIVE: The addition of magnetic resonance imaging (MRI) to mammography for surveillance of women with BRCA mutations significantly increases sensitivity but lowers specificity. This study aimed to examine whether MRI surveillance, and particularly recall, is associated with increased anxiety, depression, or breast cancer worry/distress. METHODS: Women with BRCA mutations in an MRI surveillance study were invited to complete: Hospital Anxiety and Depression Scale (HADS), Lerman's Breast Cancer Worry Scale, Breast Cancer Worry Interference Scale, and a quality of life rating at 3 time points: 1-2 weeks before (T1), 4-6 weeks after (T2) and 6 months after their annual surveillance (T3). Repeated measures analyses were performed over the 3 time points for recalled and non-recalled women. RESULTS: 55 women (30 BRCA1, 25 BRCA2) completed study instruments at T1 and T2, and 48 at T3. Eighteen women (32%) were recalled for additional imaging. At T1, 27 women (49%) were above HADS threshold for "possible cases" for anxiety (score≥8). Recalled (but not non-recalled) women had a significant increase of HADS anxiety at T2 which dropped to below baseline by T3. No group differences were observed in terms of change over time in other quantitative psychological measures. CONCLUSIONS: While breast MRI surveillance did not have a detrimental psychological impact on women with a BRCA1 or BRCA2 mutation, recalling these very high-risk women for further imaging after a false positive MRI scan temporarily increased their global anxiety.
OBJECTIVE: The addition of magnetic resonance imaging (MRI) to mammography for surveillance of women with BRCA mutations significantly increases sensitivity but lowers specificity. This study aimed to examine whether MRI surveillance, and particularly recall, is associated with increased anxiety, depression, or breast cancer worry/distress. METHODS:Women with BRCA mutations in an MRI surveillance study were invited to complete: Hospital Anxiety and Depression Scale (HADS), Lerman's Breast Cancer Worry Scale, Breast Cancer Worry Interference Scale, and a quality of life rating at 3 time points: 1-2 weeks before (T1), 4-6 weeks after (T2) and 6 months after their annual surveillance (T3). Repeated measures analyses were performed over the 3 time points for recalled and non-recalledwomen. RESULTS: 55 women (30 BRCA1, 25 BRCA2) completed study instruments at T1 and T2, and 48 at T3. Eighteen women (32%) were recalled for additional imaging. At T1, 27 women (49%) were above HADS threshold for "possible cases" for anxiety (score≥8). Recalled (but not non-recalled) women had a significant increase of HADS anxiety at T2 which dropped to below baseline by T3. No group differences were observed in terms of change over time in other quantitative psychological measures. CONCLUSIONS: While breast MRI surveillance did not have a detrimental psychological impact on women with a BRCA1 or BRCA2 mutation, recalling these very high-risk women for further imaging after a false positive MRI scan temporarily increased their global anxiety.
Authors: Joshua M Bauml; Andrea Troxel; C Neill Epperson; Roger B Cohen; Kathryn Schmitz; Carrie Stricker; Lawrence N Shulman; Angela Bradbury; Jun J Mao; Corey J Langer Journal: Lung Cancer Date: 2016-08-16 Impact factor: 5.705
Authors: Rodrigo Santa Cruz Guindalini; Yonglan Zheng; Hiroyuki Abe; Kristen Whitaker; Toshio F Yoshimatsu; Tom Walsh; David Schacht; Kirti Kulkarni; Deepa Sheth; Marion S Verp; Angela R Bradbury; Jane Churpek; Elias Obeid; Jeffrey Mueller; Galina Khramtsova; Fang Liu; Akila Raoul; Hongyuan Cao; Iris L Romero; Susan Hong; Robert Livingston; Nora Jaskowiak; Xiaoming Wang; Marcio Debiasi; Colin C Pritchard; Mary-Claire King; Gregory Karczmar; Gillian M Newstead; Dezheng Huo; Olufunmilayo I Olopade Journal: Clin Cancer Res Date: 2018-08-28 Impact factor: 12.531
Authors: Lindsey A Torbit; Jenna J Albiani; Melyssa Aronson; Spring Holter; Kara Semotiuk; Zane Cohen; Tae L Hart Journal: J Behav Med Date: 2016-01-13
Authors: Matthew Castelo; Zachary Brown; Josephine A D'Abbondanza; Nastasia V Wasilewski; Andrea Eisen; Derek Muradali; Bettina E Hansen; Eva Grunfeld; Adena S Scheer Journal: Breast Cancer Res Treat Date: 2021-07-02 Impact factor: 4.872
Authors: J S de Groot; C B Moelans; S G Elias; A Hennink; B Verolme; K P M Suijkerbuijk; A Jager; C Seynaeve; P Bos; A J Witkamp; M G E M Ausems; P J van Diest; E van der Wall Journal: PLoS One Date: 2015-05-22 Impact factor: 3.240
Authors: Janie M Lee; Kathryn P Lowry; Jessica E Cott Chubiz; J Shannon Swan; Tina Motazedi; Elkan F Halpern; Anna N A Tosteson; G Scott Gazelle; Karen Donelan Journal: Breast Date: 2020-02-13 Impact factor: 4.380
Authors: A Isselhard; M Töpper; B Berger-Höger; A Steckelberg; H Fischer; F Vitinius; K Beifus; J Köberlein-Neu; R Wiedemann; K Rhiem; R Schmutzler; S Stock Journal: Trials Date: 2020-06-08 Impact factor: 2.279